Physician profile
Jamal Joudeh
NPI 1922214352
$21,327.95
in general payments reported to CMS, 2019-2025
48 companies · $7,322 in 2025
The $7,322 reported for 2025 was more than what 86% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,019 · 2021: $1,828 · 2022: $6,033 · 2023: $2,928 · 2024: $1,198 · 2025: $7,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,188 · Food and Beverage: $3,438 · Honoraria: $1,375 · Travel and Lodging: $1,362 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,187.50 |
| Food and Beverage | $3,437.87 |
| Honoraria | $1,375.00 |
| Travel and Lodging | $1,361.97 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $6,551.39 | 2022-2025 | Trodelvy |
| Incyte Corporation | $2,926.80 | 2022-2025 | Monjuvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,370.66 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,605.60 | 2019-2024 | |
| Karyopharm Therapeutics INC. | $1,550.00 | 2021 | |
| G1 Therapeutics, INC. | $1,288.81 | 2023 | Cosela |
| Aadi Bioscience, INC. | $1,000.00 | 2023 | Fyarro |
| Janssen Biotech, INC. | $476.00 | 2019-2025 | Darzalex, Talvey, Tecvayli |
| Astellas Pharma US INC | $404.95 | 2019-2025 | Xtandi, Padcev |
| Novartis Pharmaceuticals Corporation | $316.54 | 2019-2025 | |
| Genentech USA, INC. | $275.46 | 2019-2025 | Tecentriq, Polivy, Tecentriq Hybreza |
| Regeneron Healthcare Solutions, INC. | $263.02 | 2023-2025 | Libtayo |
| Celgene Corporation | $199.07 | 2022-2025 | Reblozyl, Pomalyst |
| Merck Sharp & Dohme LLC | $186.52 | 2024-2025 | Keytruda, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $166.31 | 2022-2025 | Opdivo, Krazati, Opdualag |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamal Joudeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.